Novo Nordisk (NVO) Earnings: Results, Guidance and Stock Reaction
Novo Nordisk's latest report was Q3 2026 on November 4, 2026 (before the open): Beat and raise, and the stock moved +6.2% on it. Below: the numbers vs Wall Street, then every quarter we've explained in plain English.
Latest: Q3 2026 vs consensus
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| Sales | DKK 79.2B (+4% at constant currency) | DKK 73.6B (FactSet via CNBC) | Beat |
| Adjusted operating profit | DKK 31.7B (+27% at constant currency) | DKK 28.6B (CNBC) | Beat |
| EPS | DKK 5.79 | DKK 5.10 (CNBC) | Beat |
| Wegovy pill sales | DKK 5.4B | about DKK 4.5B (CNBC) | Beat |
| FY2026 adj. sales and operating profit growth guidance | -2% to +2% at constant currency (was -6% to flat) | n/a | Raised |
Full NVO Q3 2026 explainer: what mattered, the reaction and Max's verdict →
Every Novo Nordisk report we've explained
- Q3 2026 (November 4, 2026, before the open): Beat and raise · stock +6.2% after
Get the next NVO report explained in your inbox.
Every big earnings report in plain English: beat or miss, guidance, and how the stock took it. No spam, unsubscribe anytime.
FAQ
Did Novo Nordisk (NVO) beat earnings last quarter?
In Q3 2026, reported November 4, 2026, Novo Nordisk came in Beat and raise. Sales: DKK 79.2B (+4% at constant currency) vs DKK 73.6B (FactSet via CNBC); Adjusted operating profit: DKK 31.7B (+27% at constant currency) vs DKK 28.6B (CNBC); EPS: DKK 5.79 vs DKK 5.10 (CNBC).
When did Novo Nordisk last report earnings?
Novo Nordisk reported Q3 2026 results on November 4, 2026, before the open.
Earnings, explained in plain English. Free at 7 AM.
Every morning: who beat, who missed, what the guidance means and how the stock took it, plus 3-month stock calls graded vs the S&P 500.